[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebral-aneurysm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebral-aneurysm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,39,70,92,122,150,183,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100373330","phase-2-effect-of-sirolimus-on-molecular-alterations-in-cerebral-aneurysms-100373330",false,"NCT04141020","Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms","Inclusion Criteria:\n\n1. Undergoing one of the following procedures at Jackson Memorial Hospital:\n\n   * Clipping of an unruptured cerebral artery aneurysm\n   * Endovascular treatment of unruptured cerebral aneurysms (including those receiving coiling)\n2. ≥ 18 years of age\n3. Willing and able to give informed consent\n\nExclusion Criteria:\n\n1\\) Subjects meeting any of the following criteria will be excluded:\n\n* Dissecting, traumatic, or mycotic brain aneurysm.\n* Women who are pregnant, or have a positive urine or blood (β-hCG) pregnancy test.\n* Women who are breastfeeding.\n* Any clinically significant psychiatric or psychological disease, which would preclude the patient from completing the protocol.\n* Patients with known Human Immunodeficiency Virus (HIV) infection or other known immunodeficiency.\n* Patient with renal or liver failure\n* Interstitial pneumonitis\n* History of lymphoma\n* History of skin cancer\n* Hypersensitivity to sirolimus\n* Severe or unstable concomitant condition disease or chronic condition, which in the opinion of the investigator could affect assessment of the safety or efficacy of study intervention.","ALL","18 Years",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.",[25],"Cerebral Aneurysm","RECRUITING","2026-03-18",{"date":29,"type":30},"2026-03-23","ACTUAL",{"date":32,"type":30},"2021-10-27",{"date":34,"type":19},"2026-11-01",{"name":36,"class":37},"University of Miami","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":38},"100626641","nirs-and-bis-monitoring-during-cerebral-aneurysm-coiling-100626641","NCT07438275","NIRS and BIS Monitoring During Cerebral Aneurysm Coiling","Evaluation of Near-Infrared Spectroscopy and Bispectral Index Monitoring During Cerebral Aneurysm Coil Embolization","NIRSBIS-ANEUR","* Age ≥18 years\n* Patients scheduled for endovascular coil embolization for intracranial (cerebral) aneurysm\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Undergoing the procedure under general anesthesia\n* Ability to provide written informed consent Criteria\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent\n* History of severe cerebrovascular disease other than the target aneurysm\n* Severe cardiac, pulmonary, hepatic, or renal dysfunction\n* Pre-existing neurological deficits interfering with NIRS or BIS interpretation\n* Known scalp or skin conditions preventing proper placement of NIRS or BIS sensors\n* Emergency procedures\n* Pregnancy -","75 Years",{"count":49,"type":19},75,"OBSERVATIONAL","This prospective observational study aims to evaluate the effectiveness of Near-Infrared Spectroscopy (NIRS) and Bispectral Index (BIS) monitoring during endovascular coil embolization of cerebral aneurysms under general anesthesia. Changes in regional cerebral oxygen saturation (rSO₂) measured by NIRS will be assessed in relation to BIS values and hemodynamic parameters throughout the procedure.\n\nThe frequency, duration, and severity of cerebral desaturation episodes detected by NIRS, as well as their association with anesthetic depth and hemodynamic fluctuations, will be analyzed. The study does not involve any additional intervention beyond routine clinical monitoring.",[25],[54,55,56,57,58,59],"Near-Infrared Spectroscopy","Bispectral Index","Cerebral Oxygenation","Neuroanesthesia","Endovascular Treatment","Coil Embolization","NOT_YET_RECRUITING","2026-02-22",{"date":63,"type":30},"2026-02-27",{"date":65,"type":19},"2026-03",{"date":67,"type":19},"2026-10",{"name":69,"class":37},"Dokuz Eylul University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100562271","parent-artery-reconstruction-for-small-unruptured-cerebral-aneurusms-using-flow-diverters-a-multicenter-randomized-trialparat-mt-100562271","NCT06600997","Parent Artery Reconstruction for Small Unruptured Cerebral Aneurusms Using Flow DiverTers: a Multicenter Randomized Trial(PARAT-MT)","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Previously unruptured saccular cerebral aneurysm arising from intradural segments of the internal carotid artery and intracranial segments of the vertebral artery.\n3. Measuring ≤10mm in maximum diameter\n4. Subjects capable of understanding the study's purpose, willing to participate, and have signed an informed consent form.\n\nExclusion Criteria:\n\n1. Subjects with two or more multiple aneurysms requiring treatment within one year.\n2. Subjects with arteriovenous malformations or moyamoya disease.\n3. Subjects with ruptured, recurrent, or dissecting aneurysms.\n4. Subjects with symptomatic cerebral stenosis \\>70%;\n5. Subjects who have experienced a stroke (cerebral hemorrhage, cerebral infarction) within the past month.\n6. Clinical condition is extremely poor with a modified Rankin score of ≥3.\n7. Subjects planned for surgical\u002Finterventional procedures within three months.\n8. Subjects deemed inappropriate for interventional treatment by the investigator (e.g., no suitable vascular access, excessively tortuous vessels, difficult stent delivery, etc.).\n9. Subjects with severe comorbidities, unsuitable for anesthesia or endovascular surgery (e.g., major cardiac, pulmonary, hepatic, splenic, renal diseases, atrial fibrillation ,brain tumors, severe active infections, disseminated intravascular coagulation, history of severe mental illness).\n10. Subjects unable to tolerate antiplatelet or anticoagulant therapy.\n11. Subjects who has had or are likely to have a severe reaction to contrast media.\n12. Subjects with a history of allergy to nickel-titanium, cobalt-chromium, or platinum-tungsten alloys.\n13. Subjects who have participated in other drug or medical device clinical trials and have not reached the primary endpoint time limit.\n14. Pregnant or breastfeeding women.\n15. Subjects with an expected lifespan of less than 12 months.\n16. Subjects deemed by the investigator to have poor compliance, unable to complete the study as required.",{"count":77,"type":19},1008,[79],"NA","A prospective, multicenter, randomized controlled clinical trial with open-label treatment and blinded endpoint assessment.",[82,25],"Cerebral Aneurysm Unruptured","2025-01-01",{"date":85,"type":30},"2025-01-03",{"date":87,"type":19},"2025-01-15",{"date":89,"type":19},"2031-10-30",{"name":91,"class":37},"Changhai Hospital",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":20,"phases":101,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":38},"100498934","clinical-trial-for-the-validation-of-ar-based-neuronavigation-system-100498934","NCT05776706","Clinical Trial for the Validation of AR Based Neuronavigation System","Clinical Trial for the Evaluation of the Accuracy of Augmented Reality Based Neuronavigation System","Inclusion Criteria:\n\n* Adult patients aged 18 years or older who underwent MRI or CT scan due to brain tumor or cerebrovascular disease\n* Adult patients aged 18 years or older who need surgical treatment using navigation for brain tumor or cerebrovascular disease\n\nExclusion Criteria:\n\n* Cases where application of navigation is not necessary according to the judgment of the researcher or surgeon\n* When the patient or guardian does not agree\n* Patients with anatomical deformation due to previous surgery or requiring emergency surgery","85 Years",{"count":18,"type":19},[79],"The goal of this clinical trial is to test augmented reality (AR) based neuronavigation system in surgeries for patients of brain neoplasm or cerebral vascular disease. The main questions it aims to answer are:\n\n• AR based neuronavigation system can achieve accuracy that is not inferior to conventional intraoperative navigation system.\n\nParticipants will participate the study after informed consent. When participants undergo surgery for their brain tumor, we will set up 2 types of neuronavigation, conventional navigation system and developed AR based neuronavigation system. Surgeon will plan and conduct surgery based on only conventional navigation system, but 3D errors at several selected points between two types of navigation will be measured and analyzed.",[104,25,105,106],"Brain Neoplasms","Cerebral Arteriovenous Malformation","Navigation, Spatial",[108,109,110,111,112],"augmented reality","neuronavigation","brain neoplasms","cerebral arteriovenous malformation","cerebral aneurysm","2024-11-30",{"date":115,"type":30},"2024-12-03",{"date":117,"type":19},"2025-05-01",{"date":119,"type":19},"2027-12-31",{"name":121,"class":37},"Seoul National University Hospital",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100531576","prospective-single-arm-multicenter-study-to-evaluate-the-effectiveness-and-safety-of-endovascular-treatment-in-patients-with-cerebral-aneurysms-using-p64-and-p48-flow-diverter-stents-100531576","NCT06201598","Prospective, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Endovascular Treatment in Patients With Cerebral Aneurysms Using P64 and P48 Flow-Diverter Stents","pSPAIN_HPC","Inclusion Criteria:\n\n* Patients over 18 years old with incidental, symptomatic, and\u002For ruptured cerebral aneurysms.\n* Signed informed consent by the patient or their representative.\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Absence of signed informed consent by the patient or their representative.\n* Known, medically untreatable allergy to iodinated contrast.\n* Pregnant women or those breastfeeding.",{"count":130,"type":19},100,"The use of flow-diverting stents for the endovascular treatment of cerebral aneurysms has proven to be effective and efficient in several clinical studies, leading to its widespread adoption. Devices with a higher number of filaments have a greater flow-diverting effect and less variation when there are changes in the caliber of the underlying vessel or in curved vessels. However, ischemic complications secondary to their implantation have been reported, prompting the development of various strategies to reduce their thrombogenicity. Phenox is the only company to date that has developed an anti-thrombogenic coating, known as HPC (Hydrophilic Polymer Coating), which, when applied to the p64 MW HPC and p48 MW HPC devices, has shown to reduce the likelihood of thromboembolic complications associated with their implantation.",[25,133],"Thromboembolic Disease",[135,136,137,138,139],"Cerebral aneurysm","Flow-diverting stents","Thrombogenicity","p64 MW HPC","p48 MW HPC","2024-11-20",{"date":142,"type":30},"2024-11-22",{"date":144,"type":30},"2024-01-12",{"date":146,"type":19},"2025-12-15",{"name":148,"class":37},"Hospital Universitario Central de Asturias",11,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":20,"phases":159,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100357638","the-rise-trial-a-randomized-trial-on-intra-saccular-endobridge-devices-100357638","NCT03936647","The RISE Trial: A Randomized Trial on Intra-Saccular Endobridge Devices","RISE","Inclusion Criteria:\n\n* patient with an intracranial aneurysm in whom WEB is considered an appropriate therapeutic option by the participating clinician\n* aneurysm of maximum diameter of 4-11 mm\n* may include (but are not restricted to) saccular bifurcation aneurysms of the middle cerebral artery, basilar bifurcation, carotid terminus, or anterior communicating artery aneurysms\n* Recurring, persistent aneurysm after previous treatment can be included so long as the treating physician judges the aneurysm morphology to be appropriate.\n* Ruptured aneurysms with WFNS ≤ 3\n\nExclusion Criteria:\n\n* Absolute contraindication to surgery, endovascular treatment or anesthesia\n* Patients unable to give informed consent\n* diameter of the aneurysm ≤ 4 mm but ≥ 11 mm\n* Ruptured aneurysms with WFNS 4 or 5",{"count":158,"type":19},250,[79],"Intracranial bifurcation aneurysms are commonly repaired with surgical and with endovascular techniques. Wide-necked bifurcation aneurysms (WNBA) are a difficult subset of aneurysms to successfully repair endovascularly, and a number of treatment adjuncts have been designed. One particularly promising innovation is the WEB (Woven EndoBridge), which permits placement of an intra-saccular flow diverting mesh across the aneurysm neck, but which does not require anti-platelet agent therapy. Currently, which treatment option leads to the best outcome for patients with WNBA remains unknown. There is a need to offer treatment with the WEB within the context of a randomized care trial, to patients currently presenting with aneurysms thought to be suitable for the WEB.",[162,163,164,165,25],"Intracranial Aneurysm","Brain Aneurysm","Unruptured Cerebral Aneurysm","Ruptured Cerebral Aneurysm",[167,112,168,169,170,171,172],"intracranial aneurysm","brain aneurysm","unruptured cerebral aneurysm","ruptured cerebral aneurysm","WEB embolization device","embolization","2024-08-13",{"date":175,"type":30},"2024-08-15",{"date":177,"type":30},"2019-07-18",{"date":179,"type":19},"2026-01",{"name":181,"class":37},"Centre hospitalier de l'Université de Montréal (CHUM)",4,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":190,"sex":15,"minAge":16,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":38},"100551186","epidemiological-insights-into-the-formation-progression-and-rupture-of-intracranial-aneurysms-a-retrospective-multi-center-hospital-based-study-in-china-100551186","NCT06456814","Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China","Epidemiological Insights Into the Formation, Progression, and Rupture of Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China","Inclusion Criteria:\n\n1. IA diagnosis (ruptured or unruptured) or exclusion by digital subtractive angiography (DSA) or by cranial computed tomography angiography (CTA) \u002F magnetic resonance angiography (MRA);\n2. Aged ≥ 18 and ≤ 18 years old;\n3. With complete demographic data including age and sex;\n4. With medical record archiving officially.\n\nExclusion Criteria:\n\n1. Missing data of age, sex or hypertensive status;\n2. Age \\\u003C18 or \\>80 years;\n3. Pregnancy;\n4. With a history of intracranial arteriovenous malformation, Moyamoya, polycystic kidney disease, Ehlers-Danlos syndrome, Gronblad-Strandberg syndrome, or Marfan syndrome;\n5. Suspicion for dissecting or mycotic aneurysms or aneurysm-like lesions that were indistinguishable from the infundibulum, fenestration, dilation, or atherosclerotic remodeling on structural imaging scans.",true,"80 Years",{"count":193,"type":19},30000,"This is a retrospective, hospital-based and multi-center study aiming at investigating the potential exposures associated with the formation, progression, and rupture of intracranial aneurysms in Chinese population.",[162,196,25,163],"Subarachnoid Hemorrhage, Aneurysmal",[198,199,200],"Intracranial aneurysm","Clinical epidemiology","Exposures","2024-06-07",{"date":203,"type":30},"2024-06-13",{"date":205,"type":30},"2010-01-01",{"date":207,"type":19},"2026-12-31",{"name":209,"class":37},"Zhujiang Hospital",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":242},"100513152","registry-of-multicenter-brain-heart-comorbidity-in-china-100513152","NCT05961748","Registry of Multicenter Brain-Heart Comorbidity in China","BHC-C","Inclusion Criteria:\n\n* age \\> 18 years old\n* Any of newly diagnosed cardiovascular-related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \\[i.e., ACS\\], I46 (cardiac arrest), I48 (Atrial fibrillation\u002Fflutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).\n\nExclusion Criteria:\n\n·refuse to participate in the registry",{"count":218,"type":19},100000,"This study is a multi-center, prospective, registry study. This research was supported by the National Key Research and Development Program. To establish a domestic multi-center, large-scale \"brain-heart comorbidity\" dynamic database platform including clinical, sample database, image and other multi-dimensional information requirements, through the construction of a multi-center intelligent scientific research integration platform based on artificial intelligence.\n\nAny of newly diagnosed cardiovascular related diseases were identified via ICD-10-CM codes: I21, I22, I24 (Ischaemic heart diseases) \\[i.e., ACS\\], I46 (cardiac arrest), I48 (Atrial fibrillation\u002Fflutter), I50 (Heart failure), I71 (Aortic disease), I60 (subarachnoid hemorrhage), I61 (intracerebral hemorrhage), I63 (Cerebral infarction), I65 (Occlusion and stenosis of precerebral arteries), I66 (Occlusion and stenosis of cerebral arteries), I67.1 (cerebral aneurysm), I67.5 (moyamoya diseases), Q28.2 (Arteriovenous malformation of cerebral vessels).\n\nThe data is stored on the brain-heart comorbidity warehouse via a physical server at the institution's data centre or a virtual hosted appliance. The brain-heart comorbidity platform comprises of a series of these appliances connected into a multicenter network. This network can broadcast queries to each appliance. Results are subsequently collected and aggregated. Once the data is sent to the network, it is mapped to a standard and controlled set of clinical terminologies and undergoes a data quality assessment including 'data cleaning' that rejects records which do not meet the brain-heart comorbidity quality standards. The brain-heart comorbidity warehouse performs internal and extensive data quality assessment with every refresh based on conformance, completeness, and plausibility (http:\u002F\u002F10.100.101.65:30080\u002Flogin).",[221,222,223,224,225,226,227,228,229,230,25,231,232],"Ischemic Heart Disease","Cardiac Arrest","Atrial Fibrillation","Heart Failure","Aortic Diseases","Subarachnoid Hemorrhage","Intracerebral Hemorrhage","Cerebral Infarction","Occlusion and Stenosis of Precerebral Arteries","Occlusion and Stenosis of Cerebellar Arteries","Moyamoya Disease","Arteriovenous Malformation of Cerebral Vessels","2023-09-16",{"date":235,"type":30},"2023-09-21",{"date":237,"type":30},"2012-01-01",{"date":239,"type":19},"2032-12-31",{"name":241,"class":37},"Beijing Tiantan Hospital",14]